Last reviewed · How we verify
NCT03692442
Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
trial in Lung Cancer Non-small Cell Stage IV in 80 participants. Status unknown.
31 January 2019
Quick facts
| Lead sponsor | Guangzhou Institute of Respiratory Disease |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 May 2018 |
| Primary completion | 31 January 2019 |
| Estimated completion | 31 March 2019 |
| Sites | 1 location across China |
Conditions studied
- Lung Cancer Non-small Cell Stage IV — all drugs for Lung Cancer Non-small Cell Stage IV →
Sponsor
Guangzhou Institute of Respiratory Disease
Who can join
Adults 18 to 65, any sex, with Lung Cancer Non-small Cell Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In order to understand the efficacy and side effects of lung cancer immunotherapy, at least 30 patients with lung cancer who were treated with immunotherapy were enrolled. The second-generation sequencing technology and liquid phase factor platform were used for detection, and clinical imaging and other evaluation methods were used to explore the immunotherapy efficacy and side effects affecting lung cancer。
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, et al · · 2020 · cited 58× · PMID 32317979 · DOI 10.3389/fphar.2020.00441
Verify or expand the search:
- PubMed search for NCT03692442
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Guangzhou Institute of Respiratory Disease trials
Trials by the same sponsor.
- NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
- NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
- NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
- NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
- NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03692442 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
- Last refreshed: 2 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03692442.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing